Athersys, Inc. (ATHX): Price and Financial Metrics


Athersys, Inc. (ATHX): $1.57

0.18 (+12.95%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ATHX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ATHX POWR Grades

  • Growth is the dimension where ATHX ranks best; there it ranks ahead of 59.16% of US stocks.
  • ATHX's strongest trending metric is Growth; it's been moving up over the last 148 days.
  • ATHX's current lowest rank is in the Stability metric (where it is better than 1.56% of US stocks).

ATHX Stock Summary

  • ATHX's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 1.65% of US stocks.
  • The volatility of ATHERSYS INC's share price is greater than that of 98.37% US stocks with at least 200 days of trading history.
  • ATHERSYS INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -182.53%, greater than the shareholder yield of merely 3.15% of stocks in our set.
  • Stocks that are quantitatively similar to ATHX, based on their financial statements, market capitalization, and price volatility, are NVAX, GRNA, HGEN, ARDS, and ALT.
  • Visit ATHX's SEC page to see the company's official filings. To visit the company's web site, go to www.athersys.com.

ATHX Valuation Summary

  • In comparison to the median Healthcare stock, ATHX's price/sales ratio is 36.59% higher, now standing at 2.8.
  • ATHX's price/sales ratio has moved up 2.1 over the prior 190 months.

Below are key valuation metrics over time for ATHX.

Stock Date P/S P/B P/E EV/EBIT
ATHX 2023-01-20 2.8 -1.0 -0.2 -0.1
ATHX 2023-01-19 2.8 -1.0 -0.2 -0.1
ATHX 2023-01-18 2.7 -1.0 -0.2 -0.1
ATHX 2023-01-17 2.8 -1.0 -0.2 -0.2
ATHX 2023-01-13 2.7 -1.0 -0.2 -0.1
ATHX 2023-01-12 2.6 -0.9 -0.2 -0.1

ATHX Growth Metrics

    Its 5 year cash and equivalents growth rate is now at 2.35%.
  • Its 5 year net income to common stockholders growth rate is now at -83.8%.
  • Its 4 year revenue growth rate is now at 24.68%.
ATHX's revenue has moved up $382,000 over the prior 33 months.

The table below shows ATHX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 6.015 -66.324 -81.244
2022-06-30 10.742 -75.597 -83.752
2022-03-31 8.426 -79.26 -82.703
2021-12-31 5.514 -76.185 -86.955
2021-09-30 6.062 -74.126 -87.45
2021-06-30 1.356 -74.157 -93.816

ATHX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ATHX has a Quality Grade of C, ranking ahead of 38.11% of graded US stocks.
  • ATHX's asset turnover comes in at 0.02 -- ranking 368th of 682 Pharmaceutical Products stocks.
  • INFI, NLTX, and LCTX are the stocks whose asset turnover ratios are most correlated with ATHX.

The table below shows ATHX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.020 1 7.687
2021-03-31 0.020 1 6.179
2020-12-31 0.023 1 6.796
2020-09-30 0.008 1 7.038
2020-06-30 0.000 1 6.688
2020-03-31 0.092 1 6.754

ATHX Price Target

For more insight on analysts targets of ATHX, see our ATHX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.75 Average Broker Recommendation 1.38 (Strong Buy)

ATHX Stock Price Chart Interactive Chart >

Price chart for ATHX

ATHX Price/Volume Stats

Current price $1.57 52-week high $33.25
Prev. close $1.39 52-week low $0.50
Day low $1.39 Volume 500,300
Day high $1.57 Avg. volume 362,222
50-day MA $0.87 Dividend yield N/A
200-day MA $4.80 Market Cap 17.28M

Athersys, Inc. (ATHX) Company Bio


Athersys, Inc. focuses on the research and development activities in the field of regenerative medicine. The company was founded in 1995 and is based in Cleveland, Ohio.


ATHX Latest News Stream


Event/Time News Detail
Loading, please wait...

ATHX Latest Social Stream


Loading social stream, please wait...

View Full ATHX Social Stream

Latest ATHX News From Around the Web

Below are the latest news stories about ATHERSYS INC that investors may wish to consider to help them evaluate ATHX as an investment opportunity.

Athersys shares take a wild ride while executives meet with investors

If the company's stock price stays above $1 for 10 consecutive business days, Athersys will regain compliance with a Nasdaq listing requirement.

Yahoo | January 12, 2023

Athersys to Participate in Advanced Therapies Week and Allogeneic Cell Therapies Summit Europe in January

CLEVELAND, January 11, 2023--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today their participation in two January conferences, Advanced Therapies Week presented by Phacilitate from January 17-20, 2023 in Miami, FL and the 2nd Allogeneic Cell Therapies Summit Europe from January 30-February 1, 2023 in London, UK.

Yahoo | January 11, 2023

Athersys shares rise as company managers meet with investors

For most of the last year, clinical-stage Athersys has been cutting costs to preserve its capital while looking for new partners to help launch its adult stem cell therapy.

Yahoo | January 10, 2023

Athersys Provides MultiStem Clinical Update

CLEVELAND, January 09, 2023--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, today provided an update on ongoing clinical trials with MultiStem for the treatment of patients following hemorrhagic trauma (MATRICS-1) and for the treatment of ischemic stroke (MASTERS-2). MultiStem is a proprietary off-the-shelf stem cell product in late-stage clinical trials for acute ischemic stroke, as well as trauma and other inf

Yahoo | January 9, 2023

Athersys appoints biotech veteran to board of directors

Athersys Inc., the regenerative medicine startup in Cleveland, has appointed a biotech and drug commercialization professional to its board of directors. Joseph Nolan is CEO of Jaguar Gene Therapy LLC in Lake Forest, Illinois, Athersys said in a statement. "Joe is a strong addition to our board, bringing more than 30 years of experience managing high-value global pipelines, launching multiple successful drugs and optimizing large-scale commercial operations," Ismail Kola, chairman of the Athersys board, in the company's statement.

Yahoo | January 6, 2023

Read More 'ATHX' Stories Here

ATHX Price Returns

1-mo 86.90%
3-mo -39.85%
6-mo -75.50%
1-year -92.68%
3-year -95.48%
5-year -96.49%
YTD 86.90%
2022 -96.28%
2021 -48.42%
2020 42.28%
2019 -14.58%
2018 -20.44%

Continue Researching ATHX

Here are a few links from around the web to help you further your research on Athersys Inc's stock as an investment opportunity:

Athersys Inc (ATHX) Stock Price | Nasdaq
Athersys Inc (ATHX) Stock Quote, History and News - Yahoo Finance
Athersys Inc (ATHX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7422 seconds.